1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Merck’s Keytruda: The ‘Wall Of Data’ Still Holds After ODAC Look Back

 
• By Michael McCaughan

Merck has pulled one Accelerated Approval indication for Keytruda already this year, and a second may have to be withdrawn as well. That will leave the product with 27 indications in the US – unless, of course, more are approved before the AA indications are formally pulled.

Merck & Co., Inc.’s Keytruda is on a bit of a losing streak at the US Food & Drug Administration.

The blockbuster anti-cancer therapy was turned down for a new indication in early stage breast cancer earlier this year. Merck...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers